Somite AI

Somite.ai is pioneering foundation models for human stem cells to drive novel cell therapies at scale. The company takes a full-stack approach — generating differentiation data at approximately 1,000x lower cost than traditional methods using its proprietary capsule technology, training large-scale models with unmatched predictive power, and using these models to discover, refine, and optimize high-impact applications in cell therapy. Its DeltaStem foundation model aims to transform development of therapies for conditions including diabetes, obesity, and muscular dystrophies. The founding team includes repeat AI entrepreneur Dr. Micha Breakstone (Chorus.ai, acquired for $575M), the Head of the Fundamental AI Group at MIT, and three National Academy of Science members. The company launched in January 2024 and has raised approximately $60M including a $47M Series A led by Khosla Ventures.